Next, the phase II I-SPY2 trial which aimed at treating high-risk HER2-negative stage II/III breast cancer by durvalumab combined with Olaparib and paclitaxel was utilized to further confirm the prognostic value of HRD-EXCUTE in the HRD patients.18 PARPi7 signature was constituted of 7 DNA repair genes (BRCA1, CHEK2, MAPKAPK2, MRE11A, NBN, TDG, XPA), for predicting PARP inhibitor sensitivity,25 and it was significantly correlated with HRD Score (Supplementary Fig.S2J). Here, BRCA1 is linked to breast carcinoma.